Cat. No. 5192
Chemical Name: 1-(3,4-Dihydroxybenzoyl)-6,7-dihydr
Biological ActivityHigh affinity insulin-like growth factor-1 binding protein (IGFBP) inhibitor (Ki values are 1 - 24 nM for all six human subtypes). Displaces insulin-like growth factor-1 (IGF-1) from the IGF-1:IGFBP complex and suppresses IGF1-induced proliferation of 3T3 fibroblasts. Also increases cardiomyocyte proliferation in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Choi et al (2013) In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. Development. 140 660. PMID: 23293297.
Chen et al (2001) Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. J.Med.Chem. 44 4001. PMID: 11689087.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses NBI 31772 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: NBI 31772, supplier, NBI31772, High, affinity, insulin-like, growth, factor-1, binding, proteins, inhibitors, inhibits, IGFBP-3, IGF-1, cardiomyocytes, Tocris Bioscience, Insulin and Insulin-like Receptors products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.